Ergoteles’s Mustang Bio MBIO Stock Holding History

Ergoteles’s Portfolio MBIO Stock Details MBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-48	Closed	-$14.2K	–	1551
2022 Q4	$14.2K	Sell	48 -337	-88%	-$115K	﹤0.01%	1358
2022 Q3	$136K	Sell	385 -65	-14%	-$30.1K	﹤0.01%	1300
2022 Q2	$198K	Buy	+450	New	+$249K	0.01%	1339

Other funds holding MBIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SAG

Spotlight Asset Group Oakbrook Terrace, Illinois $143M AUM 20.66% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ergoteles's MBIO Position: Q1 2023 in Review

Ergoteles sold out of Mustang Bio (MBIO) in Q1 2023, closing a stake of 48 shares — an estimated $14.2K sold.

Ergoteles first reported a position in MBIO in Q2 2022 and held it in 3 quarters. The position peaked at $198K in Q2 2022. 48 funds tracked by Wall St. Rank hold MBIO as of Q1 2023.

Ergoteles reported no remaining Mustang Bio position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 48 Mustang Bio shares in Q1 2023, an estimated $14.2K.
Ergoteles first reported a position in Mustang Bio in Q2 2022 and held it in 3 quarters.
Ergoteles's Mustang Bio position peaked at $198K in Q2 2022.
48 funds tracked by Wall St. Rank held Mustang Bio as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.